Sympathetic mechanisms, organ damage, and antihypertensive treatment

Current Hypertension Reports

Volumn 13, Issue 4, 2011, Pages 303-308

  Grassi, Guido ^a   Seravalle, Gino ^b   Dell'Oro, Raffaella ^c   Mancia, Giuseppe ^c  

^a Istituto Auxologico Italiano ^*  (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive treatment; Hypertension; Sympathetic nervous system; Target organ damage

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MICROANGIOPATHY; MULTIPLE ORGAN FAILURE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC FUNCTION; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; SYMPATHETIC NERVOUS SYSTEM;

EID: 80052575803     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0200-4     Document Type: Article

References (40)

1. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724-8. (Pubitemid 29501288)
2. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev. 2008;13:367-75.
3. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol. 2010;95:581-6.
4. Patel MB, Sterwart JM, Loud AV, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation. 1991;84:2091-100.
5. Briest W, Homagk L, Rassler B, et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension. 2004;44:410-8. (Pubitemid 39281488)
6. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension. 2010;55:270-6.
7. Perlini S, Palladini G, Ferrero I, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressureoverload hypertrophy. Hypertension. 2005;46:1213-8. (Pubitemid 41533028)
8. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-5. (Pubitemid 36961170)
9. Greenwood JP, Scott EM, Stroker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711-7. (Pubitemid 33065459)
10. Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005. (Pubitemid 46625950)
11. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baro-reflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205-9.
12. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-11.
13. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex abnormalities in heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond). 2001;101:141-6. (Pubitemid 32758555)
14. Grassi G, Seravalle G, Dell'Oro R, et al. Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. J Hypertens. 2004;22:1747-53. (Pubitemid 39141967)
15. Brunner-La Rocca HP, Esler MD, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-43. (Pubitemid 32666655)
16. Grassi G, Seravalle G, Bertinieri G, Mancia G. Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand. 2003;177:399-404. (Pubitemid 36337644)
17. Grassi G, Seravalle G, Quarti-Trevano F, et al. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873-7. (Pubitemid 37413723)
18. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009;54:690-697. This review article examines data obtained in humans regarding the role of sympathetic neural factors in the development and progression of essential hypertension.
19. Failla M, Grappiolo A, Emanuelli G, et al. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens. 1999;17:1117-23. (Pubitemid 29389559)
20. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659-82.
21. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-41.
22. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195-1201. This review highlights the potential of renal denervation as a procedure capable of lowering blood pressure in resistant hypertension.
23. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245-253.
24. Hausberg M, Kosch M, Harmalink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-9. (Pubitemid 35176304)
25. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011 Feb 7 (Epub ahead of print). This is the first report showing that adrenergic activation is detectable in the initial stages of renal failure.
26. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-9. (Pubitemid 34260428)
27. Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens. 2007;25:47-9. (Pubitemid 44885661)
28. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15:435-41. (Pubitemid 38140785)
29. Johansson M, Gao SA, Friberg P, et al. Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens. 2005;18:995-1000. (Pubitemid 41040272)
30. Mancia G, De Backer G, Dominiczak A, et al. 2007 Practice guidelines for the management of arterial hypertension: ESH-ESC task force for the management of arterial hypertension. J Hypertens. 2007;25:1751-62. (Pubitemid 47356612)
31. Grassi G. Sympathetic and baroreflex function in hypertension: implications for current and new drugs. Curr Pharm Design. 2004;10:3579-89. (Pubitemid 39386574)
32. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of circulation in essential hypertension. J Hypertens. 1998;16:1789-96. (Pubitemid 28548518)
33. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761-9. (Pubitemid 37076361)
34. Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425-30. (Pubitemid 36150866)
35. Grassi G. Neuroadrenergic effects of calcium channel blockers: a developing concept. J Hypertens. 2004;22:887-8. (Pubitemid 38680460)
36. Grassi G, Seravalle G, Turri C, et al. Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003;41:558-62. (Pubitemid 36314632)
37. Kitahara Y, Saito F, Akao M, et al. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol. 2004;43:68-73. (Pubitemid 38032066)
38. Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361-6.
39. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680-91.
40. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-34. (Pubitemid 29322156)